COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00322751
Recruitment Status : Completed
First Posted : May 8, 2006
Last Update Posted : January 7, 2010
Information provided by:
University of New Mexico

Brief Summary:
Given the activity of single-agent Topotecan in NSCLC, there is both scientific rationale and a medical interest in studying this agent in combination with radiation. In addition, Topotecan administered on a weekly basis offers advantages over the daily x 5 regimen, i.e., the convenience of administration and fewer visits to the clinic.

Condition or disease Intervention/treatment Phase
Lung Cancer Drug: Topotecan Phase 1

Detailed Description:
This is a study of chemoradiation for patient with inoperable non small cell lung cancer with poor pulmonary function. These patients have usually very limited treatment options because of the compromised lung function. Chemoradiation is usually superior to radiation alone, but has not been extensively tested in this patient population. Topotecan is a drug approved for lung cancer that has synergistic activity with radiation. The study will determine what is the safest dose of topotecan to use with radiation in this patient population

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer (NSCLC) (Stage I to IIIA)
Study Start Date : April 2006
Actual Primary Completion Date : November 2009
Actual Study Completion Date : November 2009

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: Topotecan
    The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.

Primary Outcome Measures :
  1. The primary endpoint is the establishment of the maximum tolerated dose (MTD) of topotecan given weekly with RT [ Time Frame: Treatment with topotecan will last until RT is completed. Treatment will stop if there is disease progression or unacceptable toxicity ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with histologically proven non-small cell lung cancer Stage I to IIIA.
  • Inoperable lung cancer because of poor respiratory lung function, or other medical reasons, as determined by the thoracic surgeon.
  • PS < 2
  • Age > 18 years
  • Life expectancy of > 12 weeks
  • Normal hematologic, liver, and renal function
  • No metastatic disease as determined by CT-PET scanning and bone scan.
  • No brain metastasis by MRI
  • No contraindication to radiotherapy

Exclusion Criteria:

  • Patients with uncontrolled CNS metastases.
  • Active systemic infection.
  • Serious, uncontrolled intercurrent medical or psychiatric illness.
  • Secondary active primary malignancy.
  • Inability to comply with requirements of the study.
  • Any metastases outside of the mediastinum
  • Histologically positive pleural or pericardial effusion
  • Any chemotherapy within five years prior to enrollment on this protocol
  • Prior radiotherapy administered to the chest
  • Women who are pregnant or lactating
  • FEV1 < 1 liter/minute

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00322751

Layout table for location information
United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Layout table for investigator information
Principal Investigator: Dennie Jones, MD University of New Mexico
Layout table for additonal information
Responsible Party: Dennie Jones, MD; Principal Investigator, University of New Mexico - CRTC Identifier: NCT00322751    
Other Study ID Numbers: INST 0529C
First Posted: May 8, 2006    Key Record Dates
Last Update Posted: January 7, 2010
Last Verified: November 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents